



## Sarepta Therapeutics to Participate in Upcoming Investor Conferences

6/1/26

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June:

- **Goldman Sachs 47<sup>th</sup> Annual Global Healthcare Conference**  
Fireside chat: Monday, June 8, at 10:40 a.m. ET
- **Oppenheimer CNS and Neuro-Muscular Summit**  
Investor meetings: Wednesday, June 10, 2026

The presentation for the Goldman Sachs conference will be webcast live under the investor relations section of Sarepta's website at <https://investorrelations.sarepta.com/events-presentations> and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

### **About Sarepta Therapeutics**

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.

### **Internet Posting of Information**

We routinely post information that may be important to investors in the 'For Investors' section of our website at [www.sarepta.com](http://www.sarepta.com). We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260601633179/en/>

### **Investor Contact:**

Ian Estepan, 617-274-4052  
[iestepan@sarepta.com](mailto:iestepan@sarepta.com)

Ryan Wong, 617-800-4112  
[rwong@sarepta.com](mailto:rwong@sarepta.com)

Tam Thornton, 617-803-3825  
[tthornton@sarepta.com](mailto:tthornton@sarepta.com)

### **Media Contact:**

Tracy Sorrentino, 617-301-8566  
[tsorrentino@sarepta.com](mailto:tsorrentino@sarepta.com)

Source: Sarepta Therapeutics, Inc.